scientific reports

OPEN

Placebo treatment entails resource-dependent downregulation of negative inputs

Arasch Mostauli[1,4], Jonas Rauh[1,4], Matthias Gamer[2], Christian Büchel[1], Winfried Rief[3] & Stefanie Brassen[1✉]

Clinical trials with antidepressants reveal significant improvements in placebo groups, with effects of up to 80% compared to real treatment. While it has been suggested that treatment expectations rely on cognitive control, direct evidence for affective placebo effects is sparse. Here, we investigated how cognitive resources at both the behavioral and neural levels influence the effects of positive expectations on emotional processing. Forty-nine healthy volunteers participated in a cross-over fMRI study where positive expectations were induced through an alleged oxytocin nasal spray and verbal instruction. Participants completed a spatial cueing task that manipulated attention to emotional face distractors while being scanned and were characterized regarding their general attention control ability. Placebo treatment improved mood and reduced distractibility from fearful compared to happy faces, particularly when more attentional resources were available for processing face distractors. This aligned with changes in activation and functional coupling within prefrontal-limbic networks, suggesting that expectations induce top-down regulation of aversive inputs. Additionally, neurobehavioral effects correlated with individual control ability. Our findings highlight the critical role of cognitive resources in verbally instructed placebo effects. This may be particularly relevant in patients with major depressive disorder, who often demonstrate enhanced negativity processing but have limited cognitive control capacity.

There is an ongoing debate about the influence of patient expectations on the effectiveness of antidepressant treatment, prompted by studies showing that placebo groups can achieve up to 80% of the benefits observed in groups receiving antidepressants[1–6]. Insights into the mechanisms of placebo effects on mood state and emotion processing have the potential to improve treatment strategies for depression. However, identifying mechanisms underlying placebo responses requires contrasting the placebo condition with a non-expectation control condition.

There is solid evidence that placebo treatments can substantially modulate affect[7,8]. For instance, positive expectations can reduce experimentally induced sadness[9–11], anxiety or fear[12–16] and social stress[17,18]. Moreover, placebo manipulations can enhance baseline mood states[16,19]. Interestingly, effects persist in open-label placebo studies[20–22].

Imaging studies of placebo effects in the affective domain often report an involvement of the dorsolateral prefrontal cortex (dlPFC)[14,23], the ventromedial PFC (vmPFC)[24], and the anterior cingulate cortex (ACC)[11,14,16]. Prefrontal engagement has been attributed to the construction and maintenance of instructed beliefs[25,26]. In particular, the lateral PFC seems to be pivotal for building and updating of treatment expectations, and the signaling of instructed state representations to bias perceptual processing in downstream networks[26,27].

The consistent finding of prefrontal engagement in expectation effects suggests a critical role of cognitive functioning and goal-directed control[28]. However research on the impact of cognitive function on placebo effects is heterogeneous[29–31] and mainly focused on the pain system. Far less is known about cognitive contributions to affective expectation effects, despite its relevance to clinical conditions like major depression, where prefrontal and executive functions are frequently compromised[32–35].

[1]Department of Systems Neuroscience, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany. [2]Department of Psychology, University of Würzburg, D-97070 Würzburg, Germany. [3]Department of Clinical Psychology and Psychotherapy, Philipps-University Marburg, D-35037 Marburg, Germany. [4]Arasch Mostauli and Jonas Rauh contributed equally to this work. ✉email: sbrassen@uke.de

Here, we combined the induction of positive expectations by an alleged oxytocin application with functional neuroimaging of prefrontal networks during emotional processing. Forty-nine healthy volunteers were characterized in their general ability to control attention using a visual search (Singleton) task. They then participated in a randomized, cross-over fMRI study where they performed a spatial cueing paradigm in the scanner that manipulated attentional resources available for processing emotional face distractors[36,37]. Specifically, during a dot-probe task, attention was either shifted away from emotional face distractors using directing cues (low attention to faces context) or remained on the face distractors with spatially non-directing cues (high attention to faces context) (Fig. 1B). Thus, cognitive resources were defined using both contextual and general variables.

In summary, this study aimed to investigate how neurobehavioral resources modulate the effects of positive expectations through placebo treatment. Specifically, we hypothesized that: 1. Positive expectations (i) improve mood state, and (ii) bias emotional processing of faces towards positivity (i.e., reduced processing of negative expressions and/or increased processing of positive expressions). 2. Changes in emotional processing will be modulated by (i) contextual resources (i.e., available attentional resources to process face distractors), and (ii) individuals' general cognitive control ability, assessed via a non-emotional visual search (Singleton) task. 3. The proposed behavioral effects will correspond with activation changes in neural networks involved in emotional processing and regulation[38]. Specifically, we expected increased engagement of emotion regulatory networks, including the dlPFC, and decreased involvement of emotion valuation and interference networks, such as the vmPFC/ACC and the amygdala, mirroring the proposed behavioral placebo effects. We further aimed to explore the anticipated placebo effects in prefrontal regions concerning their modulation of limbic activity using exploratory connectivity analyses, specifically the downregulation of emotion valuation/generation networks through prefrontal engagement. 4. Finally, we hypothesized that neural expectation effects in regulatory networks would be more enhanced in individuals with a higher general cognitive control ability.

Methods and materials
Participants
Fifty-five volunteers were recruited for the study, all free from psychiatric or neurological disorders, and medication. Recruitment took place from February 1, 2022, to August 10, 2022. Sample size was based on a power calculation (gpower 3.1) in order to detect small to medium effect sizes (d = 0.40) as observed in our previous work[19], assuming an alpha of 5% and a power of 90% which results in a required samples size of N = 46. Technical issues related to the stimulation computer during scanning led to the exclusion of two participants, three did not believe from the beginning that they would receive the alleged oxytocin, and one exhibited strong movement artifacts, resulting in a final sample size of N = 49 (mean age: 26.92 ± 4.23 years; 30 women). The local ethics committee approved the study (Ethikkommission der Ärztekammer Hamburg) and all methods were performed in accordance with the relevant guidelines and regulations including authorized deception. All participants gave written informed consent and were financially compensated for participation. The study has been pre-registered at the German Clinical Trials Register (DRKS00027289) on 18/01/2022 (https://drks.de/search/en/trial/DRKS00027289). All investigations including randomization were conducted by J.R. and A.M.

Experimental protocol and expectation induction
Participants attended three study days (Fig. 1A). On day 0, they underwent screening and completed a visual search task (Singleton task, see below). On day 1 and 2, separated by 1 week, participants underwent fMRI scanning. Before scanning, they received a saline nasal spray, labeled either as oxytocin (condition 'placebo') or saline (condition 'control') in a counterbalanced cross-over design (Fig. 1A). Participants were assigned to conditions using a computer-generated randomization sequence to ensure unbiased allocation. Expectations


Fig. 1. Study design and paradigm. (**A**) Timeline. (**B**) Emotion interference task with example stimuli depicting trials with high (non-directed cue) and low (directed cue) allocation of attentional resources for processing face distractors. Emotion x cue combinations were fully balanced. The paradigm was presented in three scanning blocks and mood ratings were assessed inside the scanner before scanning and after each block (VAS$_{t1-4}$). *VAS* visual analogue scale.

about positive oxytocin effects (e.g., "Oxytocin can improve mood and inhibit the perception of aversive stimuli such as fearful faces") were induced by a custom 5-minute video documentary. Participants watched the video on both days before being told whether they were in the placebo or control condition that day. Participants then self-administered a saline nasal spray, dispersing four puffs, two per nostril. To minimize any pre-existing expectation or motivation differences between days, participants were informed that it was possible to receive the same treatment on both days.

Singleton task
On the screening day, participants performed a visual search task on a computer that measures participants' ability to recruit top-down control in order to flexibly focus on or to ignore salient visual stimuli ("singleton detection mode")[39–41]. Performance in this task has previously been related to individuals' ability to allocate attentional resources trial-by-trial in the service of prioritized emotional goals[40]. For details of the task and the calculation of the Singleton score see Supplementary information.

Behavioral ratings
Mood rating
Mood state was assessed as a primary outcome using a visual analogue scale (VAS) at participants' arrival (baseline VAS_{t0}), and then inside the scanner immediately before scanning, and after each of the three scanning blocks (VAS_{t1-4}). Participants had to shift a randomly positioned cursor on a scale spanning from 'unhappy' to 'happy' with 400 incremental steps. Values were baseline corrected by subtracting VAS_{t0} from VAS_{t1-4} values.

Expectation and experience ratings
Expectation of positive mood change was assessed after nasal spray application using an 11-point-scale (0 for no expected mood enhancement and 10 for large expected mood enhancement). At the end of each study day, participants used the same scale (0 for no and 10 for a significant positive mood improvement) to indicate how they had actually experienced the mood change (both scales adapted from[42]).

Emotional interference task
In the scanner, participants performed a modified spatial cueing paradigm established in our laboratory[36,37]. Participants had to respond to left- or right-sided dot-targets, preceded by spatially informative or uninformative cues (Fig. 1B). After a 1000 ms fixation, cues appeared on neutral, happy, sad, fearful and scrambled face distractors (5° of visual angle) for 2050–2500 ms. The left- or right-sided dot target (horizontally displaced by 7°) followed for 200 ms. Participants were instructed to respond quickly and accurately by button press according to target side. They were told to ignore the faces and instructed to keep fixation throughout the task. Trials ended with a randomly chosen inter-trial-interval of 2000–3500 ms. In two-thirds of trials, a white arrowhead pointed to the target side (valid, 83%) or the opposite side (invalid, 17%). The few invalid trials aimed to maintain attention and were excluded from analyses. In one-third of all trials, a neutral, non-spatial cue indicated equal target likelihood on both sides. As demonstrated previously, without a directional cue, the attentional focus is not covertly shifted, allowing more resources for controlled face processing according to emotional preferences[36,37].

Three sessions comprised a total of 360 trials, with 1-minute breaks in between. The fully counterbalanced design had a pseudo-randomized trial order. The stimuli included 18 facial identities (9 female) from the well-validated Karolinska Directed Emotional Faces set[43], each displaying four emotional expressions, and scrambled pictures created by shuffling the luminance of the neutral face. Each picture was presented four times. Participants were trained on the task before scanning. After scanning, they rated valence and arousal (range: 1–4) for all presented faces to account for potential differences in valence categorization and arousal perception between expressions and sessions. Behavioral tasks utilized the Psychophysics Toolbox (PTB, 3.0.14) for MATLAB.

In the statistical analysis of the emotional interference task, we first used repeated measures ANOVAs (rmANOVAs) including RTs as primary outcome measures from the control condition for each emotion to assess baseline differences (i.e., interference) caused by emotional faces compared to neutral faces in the different attentional conditions. Specifically, each rmANOVA included the factors emotion (fearful, sad, or happy vs. neutral) and attention (high vs. low; i.e., non-directing vs. directing cue). In addition, arousal matched fearful and happy face conditions were directly compared with each other to address our hypotheses about effects on (increased) positivity versus (decreased) negativity processing. We then tested whether significant interferences at baseline (control condition) changed under placebo treatment using paired t-tests. Finally, repeated measures ANCOVAs were applied to control for potential covariates (day of the placebo condition) and to assess interactions with expectation intensity and cognitive control (Singleton).

Eye movement recording
Central fixation was instructed throughout the experiment and controlled by an online infrared eye-tracker (Eyelink 1000, SR Research), oriented toward the right eye. Gaze positions were sampled at 1000 Hz, allowing accurate saccade and fixation tracking. Stimulus onsets were recorded in parallel to the eye-tracking data. For details on the analysis see Supplementary information.

MR image acquisition
Imaging data were acquired on a Siemens PRISMA 3T scanner (Erlangen, Germany) using a 64-channel head coil. Multiband echo-planar imaging sequences were applied to obtain the functional imaging data (66 slices, voxel size $1.5 \times 1.5 \times 1.5$ mm, 1.55 s TR, 29 ms TE, 70° flip angle, 225 mm field of view, multiband mode with 3 bands). A T_1-weighted MPRAGE anatomical image was also obtained for functional preprocessing (voxel size of $1 \times 1 \times 1$ mm, 240 slices).

Image preprocessing and analysis

Image preprocessing and analysis were performed utilizing SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK) and custom scripts in MATLAB. Preprocessing included realign and unwarp, normalization utilizing T1 structural image information, and 4-mm smoothing. The TsDiffAna toolbox (http://www.fil.ion.ucl.ac.uk/spm/ext/#TSDiffAna) was used for image diagnostics.

Statistical analysis applied a two-level random effects approach employing the general linear model. At single subject level, onsets of all 10 conditions (5 emotions × 2 cues) and of invalid and incorrect trials (regressor of no interest) were modeled as separate regressors convolving delta functions with a canonical hemodynamic response function. Data from the placebo and control condition were defined as separate sessions and entered into a single model. To enhance signal-to-noise ratio, individual noise regressors derived from the GLMdenoise toolbox (https://kendrickkay.net/GLMdenoise/, Version 1.4), were entered as regressors of no interest into the first-level model.

Individual contrast images were then entered into second-level random-effect ANOVA models including the factors stimulus (all emotions for confirmatory analyses, happy and fearful faces for target analyses), cue and session. A simple regression model was applied for correlation analysis.

Functional connectivity was assessed using a generalized psychophysiological interaction analysis (gPPI toolbox; http://www.nitrc.org/projects/gppi). The time course from 2 mm spheres was extracted around individual peaks within the identified cluster. On the first level, adjusted time series were modeled together with onset vectors and the interaction of both. Specific interaction contrast images (i.e., fearful/happy, non-directed/directed, placebo/control) were then analyzed within second level factorial designs.

We report results corrected for FWE due to multiple comparisons. Correction was conducted at the peak level within small volume regions of interest (ROIs) for which we had an a-priori hypothesis ($p_{FWE} < 0.05$, one-sided). Data from the standard univariate activation analysis were also reported when passing a whole-brain corrected cluster threshold of $p_{FWE} < 0.05$ (two-sided, i.e., $p_{FWE} < 0.025$ for each one-sided test; cluster forming threshold $p < .001$ uncorrected).

Based on our main interest in prefrontal-limbic regulation[14,26], we created ROIs of the dlPFC, the vmPFC/ACC, and the amygdala using functional clusters from meta-analyses on neurosynth.org and anatomical masks from the AAL3 atlas[44] (Supplementary Fig. 1). We used one-sided testing to address the following hypotheses (see introduction): behavioral expectation effects are mirrored by increased regulatory activation in the dlPFC and decreased activation reflecting appraisal and emotional interference in the amygdala and the vmPFC/ACC under placebo. These univariate patterns are also reflected in an increased negative coupling between the dlPFC and emotional appraisal regions (i.e., downregulation) during placebo. Regulatory prefrontal activation is pronounced in individuals with higher cognitive control ability.

Results

Positive expectation induction enhances mood state and post-treatment valuation

Participants rated their expectation of positive mood effects as significantly higher in the placebo than in the control session ($T_{(48)} = 7.90$, $p < .001$, d = 1.13, Fig. 2A).

Baseline mood state (VAS_{t0}) did not differ between sessions ($p = .12$). rmANOVA on baseline corrected VAS values, considering 'condition' (control/placebo) and 'time' (t1-t4) demonstrated a strong condition effect ($F_{(1,48)} = 8.61$, $p = .005$, $\eta^2 = 0.15$, Fig. 2B), with higher mood ratings in placebo (mean difference of baseline corrected ratings $VAS_{t1-4} = 18.0 \pm 6.1$). There was no significant condition x time interaction ($p > .26$).

At the end of the sessions, participants reported a stronger experience of mood increase in the placebo session ($T_{(48)} = 5.14$, $p < .001$, d = 0.73, Fig. 2C). Experience of mood enhancement at placebo was directly correlated with expectation ratings ($r = .36$, $p = .012$) as well as with positive changes in VAS mood ratings compared to control ($r = .31$, $p = .029$). There was no significant correlation between expectancy and VAS ratings (all $p > .06$).

Placebo reduces distractibility by fearful faces in the high attention context

On both study days, participants showed high accuracy in task performance (errors: control: 3.0% ± 7.6%; placebo: 1.3% ± 2.0%). Replicating previous findings[36,37], attention was strongly manipulated by different cues, leading to significantly increased reaction time (RT) under the non-directing cue (NC) compared to the valid, directing cue (DC) condition in both the control ($T_{(48)} = 12.09$; $p < .001$, d = 1.73) and placebo sessions ($T_{(48)} = 10.66$; $p < .001$, d = 1.52), with no significant difference between sessions ($F_{(1,48)} = 0.04$; $p > .85$).

Due to significant data loss, we could only analyze the eye-tracking data of 27 participants who had at least 5 trials with valid eye-tracking data in each cell of the experimental paradigm. Eye-movement data show that participants were well able to maintain central fixation across conditions which is in line with our previous studies (all $p > .05$; Supplementary Fig. 2).

After-scan arousal ratings on the control day showed a significant effect of emotion ($F_{(3,46)} = 37.45$; $p < .001$, $\eta^2 = 0.71$), caused by the following ranking of arousal ratings: happy ≈ fearful > sad > neutral. Ratings did not differ between sessions ($F_{(3,46)} = 1.28$; $p > .29$). As expected, post-scan valence ratings strongly matched pre-defined emotional expressions with an overlap of 94% on each of both sessions.

rmANOVAs using reaction time values from the control day (baseline) revealed a significant main effect for fearful faces ($F(48,1) = 12.64$, $p < .001$, $\eta2 = 0.21$), indicating longer RTs when a fearful face distractor was presented compared to a neutral face distractor. No significant effects were found for happy or sad faces compared to neutral face distractors, nor was there an interaction with the attentional context (all $p > .16$; Supplementary Fig. 3).

To more closely address our hypotheses on positive relative to negative processing, we conducted a further rmANVOA including fearful and happy faces. Results showed a significant main effect of emotion ($F_{(1,48)} = 9.97$, $p = .003$, $\eta^2 = 0.17$), along with a significant emotion × attention interaction ($F_{(1,48)} = 4.69$; $p = .035$, $\eta^2 = 0.09$).

Fig. 2. Placebo effects on expectation (**A**), mood (**B**), and experience ratings (**C**). Individual data with group means and s.e.m. Effects in baseline-normalized mood ratings are depicted for each time point and as an average across time points (t1–4). *$p < .05$, ** $p < .005$, *** $p < .001$.

These effects were driven by slower responses in fearful versus happy trials, but only in the high attention to faces condition ($T_{(48)} = 3.47$, $p < .001$, d = 0.50; Fig. 3).

Comparing the bias for fearful versus happy faces in the high attention condition from baseline to the placebo session revealed a significantly decreased bias under placebo compared to control (paired t-test, $T_{(48)} = 2.23$, $p = .031$, d = 0.32), with no significant change in the low attention condition ($p > .85$). Accordingly, the abovementioned negativity bias for fearful versus neutral faces disappeared under placebo ($p > .59$). There were no placebo effects in control trials (scrambled faces across and within attentional conditions, all $p > .81$), indicating that placebo had no general effect on task performance.

Behavioral placebo effects are moderated by individual cognitive control ability

To investigate the potential modulation of placebo effects by participants' expectation ratings and cognitive control ability, as well as to control for the effect of time (day 1 vs. day 2), an ANCOVA was conducted with the factors of session (control vs. placebo), emotion (fearful vs. happy), and attention to faces (high vs. low), and the respective covariates (expectation ratings, Singleton score, and time). No significant interaction was found with subjective expectation ratings or time; however a significant relationship emerged between individual Singleton scores and the session by attention interaction ($F_{(1,45)} = 8.90$, $p = .005$, $\eta^2 = 0.17$). Post-hoc correlations revealed that this effect was due to a specific correlation of cognitive control with placebo effects on highly attended fearful faces (control $_{fearful\_nc}$ > placebo $_{fearful\_nc}$ × Singleton: $r = -.41$, $p = .004$, Fig. 4), indicating that individuals with higher cognitive control exhibited a more pronounced bias reduction.

Neural correlates of fearful face distraction decrease at placebo

Initial confirmatory analyses validated the task's attentional manipulation by demonstrating heightened activation in primary and higher order visual processing networks in response to non-directed cues compared to directed cues. Additionally, fMRI-data showed increased activity in a visual emotional network[14], involving the extrastriate visual cortex and bilateral amygdala, in response to face stimuli compared to scrambled pictures (Supplementary Fig. 4). These patterns did not differ between sessions.

In our targeted analyses, we concentrated on fearful and happy face trials, mirroring the primary behavioral outcomes. We constructed an ANOVA for fearful versus happy faces, incorporating contrast images of high versus low attention to emotional faces from both sessions (control vs. placebo), resulting in a 2 × 2 × 2 factorial design. Consistent with behavioral findings, increased activity in a widespread network in response to fearful faces compared to happy faces was observed on the control day, likely indicating heightened distractibility by fearful faces. Regions involved cortical midline structures, such as the middle cingulate cortex and the bilateral precuneus, as well as superior frontal and parietal regions (Supplementary information, Table S1).

We then examined if there was a placebo-induced reduction in the response to highly attended fearful face stimuli (control > placebo: fearful$_{nc}$ > happy$_{nc}$). Results showed significantly decreased activation under placebo in the anterior and middle cingulate cortex, left superior frontal gyrus, and precuneus (Fig. 5A). These effects

Fig. 3. Behavioral results in the emotional interference paradigm. Distraction by fearful compared to happy faces at control (***$p < .001$) was significantly reduced at placebo (interaction: $p < .04$). Findings were restricted to the high attention to faces condition. Graph depicts individual data, boxplots, mean with s.e.m., and data distribution.


Fig. 4. Correlation between behavioral findings and cognitive control ability. (**A**) Illustration of the two singleton-task conditions (for calculation of the singleton score, see Methods section) (**B**) Placebo effects on distractibility by fearful faces correlated with cognitive control ability.

were specifically observed in the high attention condition, with no activation differences in the low attention condition on the control day or in comparison to the placebo condition (see Table S1).

Fig. 5. Neural placebo effects. (**A**) Placebo-induced signal decrease in response to highly attended fearful faces in the anterior and middle cingulate cortex, and precuneus. The bar graph shows group means and s.e.m of parameter estimates extracted from the middle cingulate cortex as examples of response patterns (**C**) Placebo-induced signal increase in the right middle frontal gyrus. The bar graph shows group means and s.e.m. of mean parameter estimates extracted from individual spheres within this activation cluster. All results are $p < .05$ FWE corrected. Activations are overlaid on a standardized MNI template (display threshold $p < .001$ uncorrected).


Fig. 6. PPI and regression results. (**A**) Placebo-induced increased negative coupling of the right middle frontal gyrus with the bilateral amygdala and with the dorsal part of the ACC. (**B**) Cognitive control ability (Singleton) correlated positively with placebo-induced increased signals in a prefrontal-parietal network. All results are $p < .05$ FWE corrected. Activations are overlaid on standardized structural and rendered templates (display threshold $p < .005$ uncorrected).

Prefrontal modulation of the placebo effect

We next tested for potentially increased activation under placebo (placebo > control: fearful$_{nc}$ > happy$_{nc}$). Results revealed a significant cluster in the right anterior-lateral PFC, specifically in response to highly attended fearful faces (Fig. 5B, Supplementary Table S1).

Psychophysiological interaction (PPI) analysis was employed to explore whether the functional coupling of this prefrontal region changed under placebo compared to control treatment during the processing of highly attended fearful faces. Results demonstrated that under placebo, middle frontal gyrus activation was specifically associated with reduced BOLD responses to fearful compared to happy face distractors in the ACC/vmPFC and the bilateral amygdala (Fig. 6A, Supplementary Table S2).

Placebo-induced prefrontal-parietal activity correlates with individual ability to control attention

Finally, to examine the neural correlates of the observed link between placebo effects and cognitive control capacity, we conducted a regression analysis including the contrast images fearful$_{placebo\ vs.\ control}$ from the high attention condition and individual singleton scores as a covariate. Significant correlations emerged in the right dlPFC and the bilateral superior parietal lobe (SPL, Fig. 6B and Supplementary Table S3). Thus, individuals with better attentional control showed a stronger placebo-related increase in prefrontal-parietal networks when being confronted with fearful face distractors.

Discussion

The current findings reveal that placebo treatment, combined with positive instructions, improves subjective mood, and diminishes the processing of irrelevant, high-arousing aversive stimuli in a context with high attentional resources. This reduction in negativity processing is evident through decreased activation within emotional interference networks, accompanied by heightened involvement of the lateral PFC and its effective down-regulation of limbic appraisal networks. Importantly, participants' overall cognitive control capacity directly predicted both behavioral and prefrontal-parietal placebo effects. These results highlight the significance of resource-dependent top-down regulation in verbally instructed placebo effects on affective processing, with implications for the potential and constraints of treatment expectations, particularly within clinical contexts.

The placebo-related decrease in fearful stimulus perception aligns with prior findings on placebo analgesia and affective expectation manipulation. Many studies used a combination of verbal instructions and conditioning to maximize expectation effects[14,45,46]. Our study demonstrates that such a decrease can also be achieved through verbal instruction alone. Neurophysiologically, diminished distraction by fearful face distractors was paralleled by an active suppression of neural networks processing emotional conflicts[47,48], including the middle cingulate cortex, the superior prefrontal cortex, and the precuneus. Reduced BOLD signals in these regions indicate decreased interference due to reduced attentional distraction under placebo.

Verbally instructed placebo effects have been linked to changes in expectations and appraisal processes, primarily mediated by prefrontal brain networks influencing subcortical, limbic systems[26,49,50]. Our data support these notions, revealing reduced processing of fearful faces associated with enhanced activity in the right lateral PFC. Contrary to our hypotheses, the amygdala did not show an overall decrease in activation under placebo. However, exploratory connectivity analyses indicated an increased negative coupling of the right lateral PFC with the amygdala and the vmPFC during placebo treatment, suggesting enhanced inhibition of affective valuation processes by higher-order cognitive control. The lateral PFC, crucial for cognitively demanding explicit strategies and cognitive flexibility[51], has been associated with the top-down biasing of affective key nodes according to the placebo-instructed state[26]. This engagement may be mediated through the vmPFC, integrating information from the lateral PFC about current goals with subcortical input about stimulus relevance from the amygdala[25,26,52,53]. Thus, our data suggest that increased lateral PFC activity signals instructed beliefs about the positive effects of oxytocin and biases appraisal processes in downstream networks accordingly through the inhibition of value signals in response to high-arousing aversive stimuli.

We focused on the role of cognitive resources in verbally instructed placebo effects within the affective system. Despite striking evidence for an involvement of prefrontal-limbic top-down regulation in placebo effects across systems[25,26,54,55], results on the impact of cognitive processes are heterogeneous. For instance, previous data suggested that placebo analgesia does not rely on an active redirection of attention and is unaffected by cognitive distraction[30]. Conversely, reduced executive functioning and weaker prefrontal resting-state EEG connectivity have been associated with disrupted placebo responses in Alzheimer's disease patients[29] and cognitive reappraisal ability mediated via the dorsolateral PFC has been positively related to placebo analgesia in young adults[31]. To our knowledge, no study so far has investigated the role of cognitive resources in affective placebo effects.

We examined the impact of cognitive resources in two ways: first, as context-dependent state variable and, second, as a context-independent general capacity. Our results showed that high resources in both dimensions predicted stronger placebo effects. Replicating previous findings[36,37], our experimental paradigm effectively manipulated attentional resources for processing emotional distractors, evident in prolonged reaction times and amplified neural face processing in the high compared to the low attention condition. Placebo effects selectively manifested in trials with non-directing cues, where distraction might have been strongest during the control session, but more resources were available for voluntary attentional allocation during the placebo session. This aligns with prior research using this paradigm, showing a positivity bias in older adults confined to the high attention condition[37]. In contrast to a previous study on positive expectation effects in emotion detection[19], we did not observe a positivity bias in terms of increased distraction by happy faces under placebo. This could be attributed to divergent task instructions, specifically the distinction between emotional detection and interference. Also unlike our earlier work[19], we observed that expectation ratings in this study were only correlated with perceived mood improvement and not with neurobehavioral placebo effects. This discrepancy might arise from individual variations between objective and subjective measures of placebo effects, as well as potential limitations in the validity of our expectation assessment. Although our manipulation significantly affected expectation ratings, they were assessed only once after nasal spray application to prevent participants from becoming suspicious through repeated ratings. In addition, the order of ratings (e.g., mood rating following expectation rating) may have biased results. While this approach aimed to maintain experimental integrity, it may have limited overall validity when relying on a single, moderately scaled rating for the entire experiment.

The selective allocation of attentional resources in the service of prioritized emotional goals in a trial-by-trial manner[40,56] likely depends on individuals' general capacity to flexibly control their attention. Here we investigated the basic principle of this assumption by assessing individuals' general cognitive ability to exert attentional top-down control over salient distraction with a Singleton visual search task[57,58]. This task evaluates

the specific function of spontaneously focusing on target information over salient distraction, and has previously been related to peoples' ability to voluntarily control their attention in an emotional context[40]. Both, behavioral and neural placebo effects were directly correlated with participants' performance in this task. At the neural level, control ability was associated with a specifically activated network of visuo-spatial orienting and top-down control[59,60], comprising the right dorsolateral PFC and the bilateral superior parietal lobe. This indicates that individuals with generally higher control ability are better able to allocate their attention in line with instructed treatment effects. However, it remains unclear whether the cognitive function measured with the Singleton task serves as a general basis for expectation realization or is specifically crucial for this visuospatial attention task. This question could be addressed in future studies by using tasks that require less attentional resources (e.g., an emotion recognition task) to assess affective expectation effects and/or by evaluating other potentially relevant cognitive measures for implementing and maintaining treatment expectations (e.g., general working-memory ability).

While our study provides valuable insights into placebo effects on mood and emotional processing in healthy individuals, future research is needed to assess the translational impact of our results on clinical samples in which mood dynamics, neurocognitive processes, pre-experience, and perception of demand characteristics may differ significantly. For example, a negativity bias in depression has sometimes been observed only for sadness, but not for other negative emotions, such as anger[61,62]). Whether the effects observed in this study generalize to any negative condition where baseline distraction is significant (e.g., sad faces in depressed patients) or are restricted to distraction by highly arousing stimuli requires further investigation in depressed samples.

Conclusions

Our findings may have important implications for the understanding of expectation effects in the treatment of mood disorders with antidepressants, both in the context of active placebo treatment and as beneficial "add-on" to effective treatments[1,63,64]. Although prioritizing negative, high-arousing information is a frequent finding in healthy individuals[65–68], a pathologically enhanced focus on negative information is a key feature in clinical depression and is crucial for the persistence and prognosis of depressive symptoms[69–71]. It therefore seems intriguing that through verbal instruction alone, attentional preferences for emotional stimuli can be modified together with mood state improvements and positive treatment experience, with the latter being an important prior for future treatment success. Whether this also applies to clinical samples and how stable such effects are over time must be addressed in future studies. Patients with major depressive disorder often demonstrate deficits in prefrontally mediated cognitive control[32–35]. Our findings suggest that patients with those deficits may benefit less from verbally instructed expectations. Their expectations might be boosted by conditioning, learning and positive experiences by which more implicit, cognitively less demanding regulation could be achieved[38,72]. First studies have started to develop such procedures[4,15,23]. Together with the consideration of individual cognitive control ability this may pave the way for an individually tailored intervention in the treatment of affective disorders.

Data availability

Behavioral and imaging data that support the findings of this study have been deposited online under the following link: https://doi.org/10.6084/m9.figshare.24279538.v1.

References

1. Kirsch, I. Placebo effect in the treatment of depression and anxiety. *Front. Psychiatry* ;**10**. (2019).
2. Leuchter, A. F., Hunter, A. M., Tartter, M. & Cook, I. A. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. *Br. J. Psychiatry*. **205**, 443–449. https://doi.org/10.1192/bjp.bp.113.140343 (2014).
3. Rief, W. et al. Meta-analysis of the placebo response in antidepressant trials. *J. Affect. Disord.* **118**, 1–8. https://doi.org/10.1016/j.jad.2009.01.029 (2009).
4. Rutherford, B. R. et al. Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. *Am. J. Psychiatry*. **174**, 135–142. https://doi.org/10.1176/appi.ajp.2016.16020225 (2017).
5. Stone, M. B. et al. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US food and drug administration: individual participant data analysis. *BMJ* **378**, e067606. https://doi.org/10.1136/bmj-2021-067606 (2022).
6. Thase, M. E., Larsen, K. G. & Kennedy, S. H. Assessing the 'true' effect of active antidepressant therapy V. placebo in major depressive disorder: use of a mixture model. *Br. J. Psychiatry*. **199**, 501–507. https://doi.org/10.1192/bjp.bp.111.093336 (2011).
7. Crichton, F. et al. The power of positive and negative expectations to influence reported symptoms and mood during exposure to wind farm sound. *Health Psychol.* **33**, 1588–1592. https://doi.org/10.1037/hea0000037 (2014).
8. Geers, A. L. et al. Affect and emotions in placebo and Nocebo effects: what do we know so far? *Soc. Personal Psychol. Compass.* **15**, e12575. https://doi.org/10.1111/spc3.12575 (2021).
9. Anna, J. A., Julia, R., Julia, W., Lea, R. & Winfried, R. Placebo mechanisms in depression: an experimental investigation of the impact of expectations on sadness in female participants. *J. Affect. Disord.* **256**, 658–667. https://doi.org/10.1016/j.jad.2019.06.070 (2019).
10. Haas, J. W., Rief, W., Glombiewski, J. A., Winkler, A. & Doering, B. K. Expectation-induced placebo effect on acute sadness in women with major depression: an experimental investigation. *J. Affect. Disord.* **274**, 920–928. https://doi.org/10.1016/j.jad.2020.05.056 (2020).
11. Schaefer, M., Kühnel, A., Schweitzer, F., Enge, S. & Gärtner, M. Neural underpinnings of open-label placebo effects in emotional distress. *Neuropsychopharmacol. Off Publ Am. Coll. Neuropsychopharmacol.* **48**, 560–566. https://doi.org/10.1038/s41386-022-01501-3 (2023).
12. Meyer, B. et al. Neural mechanisms of placebo anxiolysis. *J. Neurosci. Off J. Soc. Neurosci.* **35**, 7365–7373. https://doi.org/10.1523/JNEUROSCI.4793-14.2015 (2015).

13. Meyer, B., Yuen, K. S. L., Saase, V. & Kalisch, R. The functional role of Large-scale brain network coordination in Placebo-induced anxiolysis. *Cereb. Cortex N Y N 1991.* **29**, 3201–3210. https://doi.org/10.1093/cercor/bhy188 (2019).

14. Petrovic, P. et al. Placebo in emotional processing— induced expectations of anxiety relief activate a generalized modulatory network. *Neuron* **46**, 957–969. https://doi.org/10.1016/j.neuron.2005.05.023 (2005).

15. Shafir, R., Israel, M. & Colloca, L. Harnessing the placebo effect to enhance emotion regulation effectiveness and choice. *Sci. Rep.* **13**, 2373. https://doi.org/10.1038/s41598-023-29045-6 (2023).

16. Zhang, W., Qin, S., Guo, J. & Luo, J. A follow-up fMRI study of a transferable placebo anxiolytic effect. *Psychophysiology* **48**, 1119–1128. https://doi.org/10.1111/j.1469-8986.2011.01178.x (2011).

17. Abrams, K., Kushner, M., Lisdahl Medina, K. & Voight, A. The Pharmacologic and expectancy effects of alcohol on social anxiety in individuals with social phobia. *Drug Alcohol Depend.* **64**, 219–231. https://doi.org/10.1016/S0376-8716(01)00125-9 (2001).

18. Balodis, I. M., Wynne-Edwards, K. E. & Olmstead, M. C. The stress–response-dampening effects of placebo. *Horm. Behav.* **59**, 465–472. https://doi.org/10.1016/j.yhbeh.2011.01.004 (2011).

19. Baker, J., Gamer, M., Rauh, J. & Brassen, S. Placebo induced expectations of mood enhancement generate a positivity effect in emotional processing. *Sci. Rep.* **12**, 5345. https://doi.org/10.1038/s41598-022-09342-2 (2022).

20. Hahn, A., Göhler, A. C., Hermann, C. & Winkler, A. Even when you know it is a placebo, you experience less sadness: first evidence from an experimental open-label placebo investigation. *J. Affect. Disord.* **304**, 159–166. https://doi.org/10.1016/j.jad.2022.02.043 (2022).

21. Schienle, A., Unger, I. & Schwab, D. Changes in neural processing and evaluation of negative facial expressions after administration of an open-label placebo. *Sci. Rep.* **12**, 6577. https://doi.org/10.1038/s41598-022-10567-4 (2022).

22. Sezer, D., Locher, C. & Gaab, J. Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects. *Sci. Rep.* **12**, 21219. https://doi.org/10.1038/s41598-022-25446-1 (2022).

23. Peciña, M., Heffernan, J., Wilson, J., Zubieta, J. K. & Dombrovski, A. Y. Prefrontal expectancy and reinforcement-driven antidepressant placebo effects. *Transl Psychiatry.* **8**, 1–11. https://doi.org/10.1038/s41398-018-0263-y (2018).

24. Ellingsen, D-M. et al. Placebo improves pleasure and pain through opposite modulation of sensory processing. *Proc. Natl. Acad. Sci.* **110**, 17993–17998. https://doi.org/10.1073/pnas.1305050110 (2013).

25. Geuter, S., Koban, L. & Wager, T. D. The cognitive neuroscience of placebo effects: concepts, predictions, and physiology. *Annu. Rev. Neurosci.* **40**, 167–188. https://doi.org/10.1146/annurev-neuro-072116-031132 (2017).

26. Koban, L., Jepma, M., Geuter, S. & Wager, T. D. What's in a word? How instructions, suggestions, and social information change pain and emotion. *Neurosci. Biobehav Rev.* **81**, 29–42. https://doi.org/10.1016/j.neubiorev.2017.02.014 (2017).

27. Wager, T. D. et al. Placebo-Induced changes in fMRI in the anticipation and experience of pain. *Science* **303**, 1162–1167. https://doi.org/10.1126/science.1093065 (2004).

28. Corbetta, M. & Shulman, G. L. Control of goal-directed and stimulus-driven attention in the brain. *Nat. Rev. Neurosci.* **3**, 201–215. https://doi.org/10.1038/nrn755 (2002).

29. Benedetti, F. et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. *Pain* **121**, 133–144. https://doi.org/10.1016/j.pain.2005.12.016 (2006).

30. Buhle, J. T., Stevens, B. L., Friedman, J. J. & Wager, T. D. Distraction and placebo: two separate routes to pain control. *Psychol. Sci.* **23**, 246–253. https://doi.org/10.1177/0956797611427919 (2012).

31. van der Meulen, M., Kamping, S. & Anton, F. The role of cognitive reappraisal in placebo analgesia: an fMRI study. *Soc. Cogn. Affect. Neurosci.* **12**, 1128–1137. https://doi.org/10.1093/scan/nsx033 (2017).

32. Grahek, I., Shenhav, A., Musslick, S., Krebs, R. M. & Koster, E. H. W. Motivation and cognitive control in depression. *Neurosci. Biobehav Rev.* **102**, 371–381. https://doi.org/10.1016/j.neubiorev.2019.04.011 (2019).

33. Millan, M. J. et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nat. Rev. Drug Discov.* **11**, 141–168. https://doi.org/10.1038/nrd3628 (2012).

34. Pizzagalli, D. A. & Roberts, A. C. Prefrontal cortex and depression. *Neuropsychopharmacol. Off Publ Am. Coll. Neuropsychopharmacol.* **47**, 225–246. https://doi.org/10.1038/s41386-021-01101-7 (2022).

35. Snyder, H. R. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. *Psychol. Bull.* **139**, 81–132. https://doi.org/10.1037/a0028727 (2013).

36. Brassen, S., Gamer, M., Rose, M. & Büchel, C. The influence of directed Covert attention on emotional face processing. *NeuroImage* **50**, 545–551. https://doi.org/10.1016/j.neuroimage.2009.12.073 (2010).

37. Brassen, S., Gamer, M. & Büchel, C. Anterior cingulate activation is related to a positivity Bias and emotional stability in successful aging. *Biol. Psychiatry.* **70**, 131–137. https://doi.org/10.1016/j.biopsych.2010.10.013 (2011).

38. Etkin, A., Büchel, C. & Gross, J. J. The neural bases of emotion regulation. *Nat. Rev. Neurosci.* **16**, 693–700. https://doi.org/10.1038/nrn4044 (2015).

39. Costello, M. C., Madden, D. J., Shepler, A. M., Mitroff, S. R. & Leber, A. B. Age-related preservation of top-down control over distraction in visual search. *Exp. Aging Res.* **36**, 249–272. https://doi.org/10.1080/0361073X.2010.484719 (2010).

40. Sasse, L. K., Gamer, M., Büchel, C. & Brassen, S. Selective control of attention supports the positivity effect in aging. *PLOS ONE.* **9**, e104180. https://doi.org/10.1371/journal.pone.0104180 (2014).

41. Theeuwes, J. & Burger, R. Attentional control during visual search: the effect of irrelevant singletons. *J. Exp. Psychol. Hum. Percept. Perform.* **24**, 1342–1353. https://doi.org/10.1037/0096-1523.24.5.1342 (1998).

42. Rief, W. et al. Generic rating scale for previous treatment experiences, treatment expectations, and treatment effects (GEEE) (2021).

43. Lundqvist, D., Flykt, A. & Öhman, A. The Karolinska directed emotional faces - KDEF, CD ROM. (1998).

44. RollsET, Huang, C-C., Lin, C-P., Feng, J. & Joliot, M. Automated anatomical labelling atlas 3. *NeuroImage* **206**, 116189. https://doi.org/10.1016/j.neuroimage.2019.116189 (2020).

45. Colloca, L. Chapter Eight - Placebo effects in pain. In: Witek NP, Goetz CG, Stebbins GT, editors. *Int. Rev. Neurobiol.* 153, Academic Press; pp. 167–85. (2020). https://doi.org/10.1016/bs.irn.2020.04.001

46. Tinnermann, A., Geuter, S., Sprenger, C., Finsterbusch, J. & Büchel, C. Interactions between brain and spinal cord mediate value effects in Nocebo hyperalgesia. *Science* **358**, 105–108. https://doi.org/10.1126/science.aan1221 (2017).

47. Chen, T. et al. A domain-general brain network underlying emotional and cognitive interference processing: evidence from coordinate-based and functional connectivity meta-analyses. *Brain Struct. Funct.* **223**, 3813–3840. https://doi.org/10.1007/s00429-018-1727-9 (2018).

48. Song, S. et al. The influence of emotional interference on cognitive control: A meta-analysis of neuroimaging studies using the emotional Stroop task. *Sci. Rep.* **7**, 2088. https://doi.org/10.1038/s41598-017-02266-2 (2017).

49. Benedetti, F. Placebo effects: from the Neurobiological paradigm to translational implications. *Neuron* **84**, 623–637. https://doi.org/10.1016/j.neuron.2014.10.023 (2014).

50. Schwarz, K. A., Pfister, R. & Büchel, C. Rethinking explicit expectations: connecting placebos, social cognition, and contextual perception. *Trends Cogn. Sci.* **20**, 469–480. https://doi.org/10.1016/j.tics.2016.04.001 (2016).

51. Friedman, N. P. & Robbins, T. W. The role of prefrontal cortex in cognitive control and executive function. *Neuropsychopharmacology* **47**, 72–89. https://doi.org/10.1038/s41386-021-01132-0 (2022).

52. Haber, S. N. & Knutson, B. The reward circuit: linking primate anatomy and human imaging. *Neuropsychopharmacol. Off Publ Am. Coll. Neuropsychopharmacol.* **35**, 4–26. https://doi.org/10.1038/npp.2009.129 (2010).

53. Lapate, R. C., Ballard, I. C., Heckner, M. K. & D'Esposito, M. Emotional context sculpts action goal representations in the lateral frontal pole. *J. Neurosci.* **42**, 1529–1541. https://doi.org/10.1523/JNEUROSCI.1522-21.2021 (2022).
54. Atlas, L. Y. & Wager, T. D. A Meta-analysis of brain mechanisms of placebo analgesia: consistent findings and unanswered questions. In: (eds Benedetti, F., Enck, P., Frisaldi, E. & Schedlowski, M.) Placebo, Berlin, Heidelberg: Springer; 37–69. https://doi.org/10.1007/978-3-662-44519-8_3. (2014).
55. Zunhammer, M., Spisák, T., Wager, T. D. & Bingel, U. Meta-analysis of neural systems underlying placebo analgesia from individual participant fMRI data. *Nat. Commun.* **12**, 1391. https://doi.org/10.1038/s41467-021-21179-3 (2021).
56. Cisler, J. M. & Koster, E. H. W. Mechanisms of attentional biases towards threat in anxiety disorders: an integrative review. *Clin. Psychol. Rev.* **30**, 203–216. https://doi.org/10.1016/j.cpr.2009.11.003 (2010).
57. Theeuwes, J. Cross-dimensional perceptual selectivity. *Percept. Psychophys.* **50**, 184–193. https://doi.org/10.3758/bf03212219 (1991).
58. Theeuwes, J. Perceptual selectivity for color and form. *Percept. Psychophys.* **51**, 599–606. https://doi.org/10.3758/bf03211656 (1992).
59. Corbetta, M., Patel, G. & Shulman, G. L. The reorienting system of the human brain: from environment to theory of mind. *Neuron* **58**, 306–324. https://doi.org/10.1016/j.neuron.2008.04.017 (2008).
60. Shomstein, S. Cognitive functions of the posterior parietal cortex: top-down and bottom-up attentional control. *Front. Integr. Neurosci.* ;**6**. (2012).
61. Sanchez, A., Vazquez, C., Marker, C., LeMoult, J. & Joormann, J. Attentional disengagement predicts stress recovery in depression: an eye-tracking study. *J. Abnorm. Psychol.* **122**, 303–313. https://doi.org/10.1037/a0031529 (2013).
62. Gotlib, I. H., Krasnoperova, E., Yue, D. N. & Joormann, J. Attentional biases for negative interpersonal stimuli in clinical depression. *J. Abnorm. Psychol.* **113**, 121–135. https://doi.org/10.1037/0021-843X.113.1.121 (2004).
63. Rief, W. et al. Rethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. *Neurosci. Biobehav Rev.* **60**, 51–64. https://doi.org/10.1016/j.neubiorev.2015.11.008 (2016).
64. Rutherford, B. R. & Roose, S. P. A model of placebo response in antidepressant clinical trials. *Am. J. Psychiatry.* **170**, 723–733. https://doi.org/10.1176/appi.ajp.2012.12040474 (2013).
65. Bertini, C. & Làdavas, E. Fear-related signals are prioritised in visual, somatosensory and spatial systems. *Neuropsychologia* **150**, 107698. https://doi.org/10.1016/j.neuropsychologia.2020.107698 (2021).
66. Maratos, F. A. & Pessoa, L. Chapter 6 - What drives prioritized visual processing? A motivational relevance account. In: Srinivasan N, editor. Prog. Brain Res., vol. 247, Elsevier; pp. 111–48. (2019). https://doi.org/10.1016/bs.pbr.2019.03.028
67. Norris, C. J. The negativity bias, revisited: evidence from neuroscience measures and an individual differences approach. *Soc. Neurosci.* **16**, 68–82. https://doi.org/10.1080/17470919.2019.1696225 (2021).
68. Schindler, S. & Bublatzky, F. Attention and emotion: an integrative review of emotional face processing as a function of attention. *Cortex J. Devoted Study Nerv. Syst. Behav.* **130**, 362–386. https://doi.org/10.1016/j.cortex.2020.06.010 (2020).
69. Beck, A. T. Cognitive models of depression. *J. Cogn. Psychother.* **1**, 5–37 (1987).
70. LeMoult, J., Gotlib, I. H. & Depression a cognitive perspective. *Clin. Psychol. Rev.* **69**, 51–66. https://doi.org/10.1016/j.cpr.2018.06.008 (2019).
71. Mennen, A. C., Norman, K. A. & Turk-Browne, N. B. Attentional bias in depression, Understanding mechanisms to improve training and treatment. *Curr. Opin. Psychol.* **29**, 266–273. https://doi.org/10.1016/j.copsyc.2019.07.036 (2019).
72. Thams, F. & Brassen, S. The need to change: is there a critical role of midlife adaptation in mental health later in life? *eLife* **12**, e82390. https://doi.org/10.7554/eLife.82390 (2023).

Acknowledgements

Author contributions

S.B. conceptualized the study, analysed and discussed the data, and wrote the main manuscript text. A.M. performed the study, discussed the data, and wrote the main manuscript text. J.R. performed the study, and analysed the data. M.G. analysed the eyetracking data, and discussed the data. W.F. and C.B. discussed the data. All authors reviewed the manuscript.

Funding

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-025-93589-y.

Correspondence and requests for materials should be addressed to S.B.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.